arrow
Z

Zsolt Nagy

Semmelweis University
H指数:45
被引数:9,915

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Digital PCR-based quantification of miR-181a in the cerebrospinal fluid aids patient stratification in pediatric acute lymphoblastic leukemia

基于数字PCR的脑脊液miR-181a定量分析有助于小儿急性淋巴细胞白血病的患者分层

2024-11-180
OAAI
Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab

III期随机COMMODORE 1试验:从艾库努单抗转换治疗的阵发性夜间血红蛋白尿(PNH)患者中克罗瓦利单抗的2年安全性与有效性

BLOOD
IF23.1
2024-11-050
PRE
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria
2024-06-258
PRE
Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation
2023-11-211
OAAI
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study
2023-08-3113
OAAI
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
2021-07-0193
OAAI
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
2021-06-0214
OAAI
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
LANCET
IF88.5
2020-01-01317
PREAI
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
2018-02-08742
OAAI
Two transgenic mouse models for β-subunit components of succinate-CoA ligase yielding pleiotropic metabolic alterations
2016-10-1129
OAAI